| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10910846 | Lung Cancer | 2015 | 7 Pages |
Abstract
This small study demonstrated considerable toxicity and a significant pharmacokinetic interaction with a marked decrease in erlotinib exposure in the presence of dovitinib, likely mediated through CYP1A1/1A2 induction. Given the toxicity and the pharmacokinetic interaction, further investigation with this drug combination will not be pursued.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Millie Das, Sukhmani K. Padda, Adam Frymoyer, Lisa Zhou, Jonathan W. Riess, Joel W. Neal, Heather A. Wakelee,